According to the law firm press release, TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Rhe Company is developing two therapies targeting hematological malignancies and autoimmune diseases: (i) TG-1101 (ublituximab), a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes; and (ii) TGR-1202, an orally available PI3K delta inhibitor for various hematologic malignancies.

The complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business and operations. Specifically, Defendants made false and/or misleading statements and/or omitted material information concerning the GENUINE Phase III trial, assuring investors it was a “best-in-class treatment” that would be “successful” and “offer patients a novel chemo-free treatment option.” As a result of the foregoing, the Company’s statements were materially false and misleading at all relevant times.

This case was voluntarily dismissed on April 5, 2017.